Form 8-K · Current report
Fortive 8-K, filed Oct 28, 2026
- Filed
- CIK
- 0001659166
- Accession no.
- 0001659166-26-000039
Summary
Fortive reported third-quarter 2026 revenue of $1.11 billion, up 7.8% year over year (7.2% core), with GAAP diluted EPS of $0.57 and adjusted diluted EPS of $0.77, and raised its full-year 2026 adjusted EPS guidance to $3.10–$3.14, which CEO Olumide Soroye attributed to year-to-date performance and confidence in the business trajectory.
Key points
- Q3 2026 GAAP net earnings were $173 million, up 47.4% year over year, with adjusted EBITDA of $339 million, up 9.5%.
- Fortive repurchased roughly $300 million of shares in the quarter, bringing total repurchases since the launch of the new Fortive to about $2.3 billion, or roughly 43 million shares.
- The Intelligent Operating Solutions segment posted revenue of $767 million, up 9.8%, while Advanced Healthcare Solutions revenue was $340 million, up 3.7%.
- Fortive completed the separation of its former Precision Technologies segment into Ralliant Corporation on June 28, 2025, and reports the Ralliant business as discontinued operations.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On October 28, 2026, Fortive Corporation (the "Company") issued a press release announcing financial results for the quarter ended October 2, 2026. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. The information set forth in this Item 2.02 of this Current Report on Form 8-K and the press release attached hereto as Exhibit 99.1 are being furnished pursuant to Item 2.02 of Form 8-K. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.